(IN BRIEF) Sandoz has announced a major strategic collaboration with Shanghai Henlius Biotech, Inc. covering up to 10 biosimilar assets, in one of the largest biosimilar collaborations in Sandoz’s history. Under the agreement, Sandoz will receive global commercialisation rights outside … Read the full press release →
Posted in Business, Financial, Healthcare, International Trade, Investment, Law, News, Pharma & Biotech, Science, Switzerland
Tagged 02696, 39 assets, affordable medicines, Alexis Kalomparis, Basel, belimumab, Benlysta, biosimilar pipeline, biosimilars, Cardiovascular risk, cetuximab, CHINA, Chris Lewis, clinical development, commercialisation rights, Craig Marks, development agreement, early development, epidermal growth factor receptor, ERBITUX, evolocumab, global affordable medicines, global commercialisation rights outside China, healthcare savings, Henlius, HKEx, hypercholesterolaemia, ImClone LLC, ipilimumab, loss of exclusivity, lupus nephritis, manufacturing agreement, Marina Konrad-Maerk, metastatic colorectal cancer, milestone-based agreement, oncology therapy, OTCQX®, patient access, recombinant human hyaluronidase, Repatha, Richard Saynor, Samsung Bioepis, Sandoz, Sandoz and Henlius Announce Strategic Collaboration Covering Up to 10 Biosimilars, Sandoz Expands Biosimilar Pipeline Through Major Henlius Collaboration, Sandoz Secures Global Rights Outside China for Up to 10 Henlius Biosimilar Assets, SDZ, SDZNY, Shanghai Henlius Biotech, Silvia Siegfried, SIX Swiss Exchange, squamous cell carcinoma of the head and neck, strategic collaboration, subcutaneous administration, Switzerland, systemic lupus erythematosus, Tamara Hackl, Technical Development, up to 46 assets, USD 100.5 million, USD 322 million
(IN BRIEF) Novartis has confirmed its plans for a full Spin-off of its Sandoz business, with trading of new Sandoz Group AG shares and ADRs scheduled to begin on October 4, 2023. This comes after receiving shareholder approval and key … Read the full press release →
Posted in Business, Financial, Investment, Pharma & Biotech, Switzerland
Tagged ADRs, American Depositary Receipts, Novartis, Novartis ADR, OTCQX®, Sandoz, Sandoz Group AG, SDZ, shareholder, shares, SIX Exchange Regulation, SIX Swiss Exchange, SLI®, spin-off, SPI®, Swiss indices, Swiss Leader Index, Swiss Performance Index
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Digi Communications NV announces availability of Digi Spain’s H1 2026 financial results presentation
Load more...
